Blood Lithium Levels and Suicidal Events in People With Mood Disorders
Measures basal lithium in blood of adults with depression, bipolar disorder or suicidal behavior.
Plain-language title generated from the registry record
Registry title: Basal Plasma Lithium Levels and Suicidal Events
Key facts
- Where
- Montpellier, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in a current major depressive episode who have not taken lithium in the last 12 months. It includes people with and without a recent suicidal event.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Current major depressive episode (DSM-5 criteria).
- Earlier treatment
- No lithium-based treatment in the last 12 months.
Main reasons for not taking part
- Ever diagnosed with schizoaffective disorder, schizophrenia or psychosis
- Pregnancy or breastfeeding
- Deprived of freedom by a judicial or administrative decision
- Under a legal protection measure (guardianship or curators)
- Not affiliated to the French National Social Security System
Read by machine on 12 November 2026.
Where in France
- CHU MontpellierMontpellier, FranceContact: Benedicte NOBILETaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT05409794
- Record updated
- 9 August 2024
- Original description
Suicidal behavior is a major public health issue and there are currently no specific treatments for it.Read full original descriptionShow less
Basal Plasma Lithium Levels and Suicidal Events (LIPS)
Suicidal behavior is a major public health issue and there are currently no specific treatments for it.
However, lithium, the reference treatment for bipolar disorder, have been shown to be effective in preventing suicidal risk.
Apart from drug treatments, lithium is present in our environment and its levels varies from one individual to another, depending, especially, on diet.
Knowing that patients with a mood disorder generally have a poor lifestyle and a less rich and varied diet than the general population, variations in basal lithium levels can be expected in these patients.
Inclusion: 18 years old or over; Current major depressive episode according to the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria; No lithium-based treatment over the last 12 months; For suicide attempters/ideations only : suicidal event over the last 12 months; For affective controls only : no suicidal event over the last 12 months.
Exclusion: Lifetime diagnosis of schizoaffective disorder, schizophrenia or psychosis; Pregnancy or breastfeeding; Deprivation of freedom (by judicial or administrative decision); Legal protection measure (guardianship or curators); Inability to understand experimental procedures; No affiliation to the French National Social Security System; No consent to participate in the study.